GEFFY 250MG TABLETS
| Product Name | Geffy Tablet |
| Strength | 250 mg |
| Active Ingredient | Gefitinib |
| Drug Class | EGFR Tyrosine Kinase Inhibitor |
| Form | Tablet |
| Route of Administration | Oral |
| Packaging | Blister pack/bottle (as per manufacturer) |
| Storage Condition | Store below 30°C in a dry place |
| Prescription Required | Yes |
| Usage | Treatment of non-small cell lung cancer |
GEFFY 250MG TABLETS
Geffy 250mg Tablets contain gefitinib, a prescription EGFR tyrosine kinase inhibitor specifically designed for the treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). This targeted therapy is clinically proven to interfere with cancer cell growth, offering a focused approach in managing NSCLC.
Gefitinib works by blocking the signals that stimulate uncontrolled cancer cell division and proliferation. By inhibiting the EGFR pathway, Gefitinib helps slow disease progression and may improve patient outcomes when used under proper medical guidance.
Geffy is a prescription oncology product developed to support targeted treatment for non-small cell lung cancer. This oral product offers convenient administration while delivering focused EGFR inhibition. When used under medical supervision, Geffy serves as a reliable option in modern lung cancer management.
Product Features
- Oral targeted anticancer tablet
- Contains Gefitinib 250 mg
- EGFR tyrosine kinase inhibitor
- Used in EGFR-positive non-small cell lung cancer (NSCLC)
- High-specificity targeted therapy
- Once-daily oral dosing
- Manufactured under GMP-compliant standards
- Prescription-required oncology medicine
How It Helps
- Targets EGFR-positive cancer cells to slow tumor growth
- Blocks signals responsible for uncontrolled cancer cell division
- Helps manage disease progression in NSCLC patients
- Provides convenient once-daily oral targeted therapy
Reviews
There are no reviews yet.